Featured Article

Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease

Min Shi[a,1], Lu Tang[a,b,1], Jon B. Toledo[c], Carmen Ginghina[a], Hua Wang[a,d], Patrick Aro[a], Poul H. Jensen[e], Daniel Weintraub[c], Alice S. Chen-Plotkin[c], David J. Irwin[c], Murray Grossman[c], Leo McCluskey[c], Lauren B. Elman[c], David A. Wolk[c], Edward B. Lee[c], Leslie M. Shaw[c], John Q. Trojanowski[c], Jing Zhang[a,d,*]

[a]Department of Pathology, University of Washington School of Medicine, Seattle, WA, USA
[b]Department of Neurology, Peking University Third Hospital, Beijing, China
[c]Departments of Pathology and Laboratory Medicine, Psychiatry, Neurology and Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
[d]Department of Pathology, Peking University Health Science Centre and Third Hospital, Beijing, China
[e]DANDRITE-Danish Research Institute of Translational Neuroscience & Department of Biomedicine, University of Aarhus, Aarhus, Denmark

Abstract

Introduction: The ability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1–42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis.

Methods: CSF total α-syn, phosphorylated α-syn at Ser129, and AD CSF biomarkers were evaluated with Luminex immunoassays in 367 participants, followed by validation in 74 different neuropathologically confirmed cases.

Results: CSF total α-syn, when combined with amyloid β peptide 1–42 and either total tau or phosphorylated tau, improved the differential diagnosis of AD versus frontotemporal dementia, Lewy body disorders, or other neurological disorders. The diagnostic accuracy of the combined models attained clinical relevance (area under curve ∼0.9) and was largely validated in neuropathologically confirmed cases.

Discussion: Combining CSF biomarkers representing AD and Lewy body pathologies may have clinical value in the differential diagnosis of AD.

© 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Keywords: Alzheimer's disease; Differential diagnosis; Biomarkers; Cerebrospinal fluid; α-synuclein

1. Introduction

Investigations using biochemical measures in cerebrospinal fluid (CSF) as Alzheimer's disease (AD) biomarkers have shown great promise, and such CSF biomarkers have been incorporated into recent guidelines for informed diagnosis of AD [1]. Specifically, CSF markers of core AD pathology (i.e., amyloid β peptide 1–42 [Aβ$_{42}$] reflecting Aβ in plaque burden, and total tau [t-tau] and phosphorylated tau [p-tau] for assessing neurofibrillary tangles in the brain) provide both high sensitivity and specificity (80% or above) in differentiating patients with AD or mild cognitive impairment (MCI; prodromal AD) from healthy controls (HCs) [2–4]. However, the diagnostic accuracy of these CSF biomarkers in the differential diagnosis of AD and other dementias is limited (40%–80% sensitivity and specificity)

due to a substantial overlap in the CSF levels of these proteins [4–9]. A recent large-scale international multicenter study [5] suggested that the limited utility of these core CSF biomarkers to discriminate AD from a variety of related disorders could be due to the overlap in the underlying primary pathologies, and introduction of additional CSF biomarkers reflecting other types of pathologies could be of value to optimize the differential diagnosis [4,5], though reliance on clinical diagnoses might underestimate the accuracy of CSF biomarkers [10].

Among the concomitant non-AD type pathologies in AD, α-synuclein (α-syn)-positive Lewy bodies (LBs), the pathological hallmark of another family of neurodegenerative diseases including Parkinson disease (PD) and dementia with Lewy bodies (DLB), can be observed in up to 50% of familial and sporadic AD patients at autopsy [11–13]. We have reported that CSF total α-syn and phosphorylated α-syn at Ser129 (pS129) help differentiate PD from AD and other related neurodegenerative diseases [14–16]. More recently, we also found that CSF total α-syn improved the diagnostic and prognostic performance of CSF $A\beta_{42}$ and tau in AD [17,18]. In this study, to test whether inclusion of CSF α-syn that represents brain LB pathology could improve the differential diagnosis of AD and other dementias, we further evaluated the utility of CSF total α-syn and pS129 in the differential diagnosis in a relatively large clinical cohort, followed by validating our findings in a separate cohort of neuropathologically confirmed cases.

2. Methods

2.1. Subjects

Two cohorts of research participants were recruited at the AD Core Center, the Penn Memory Center, the Frontotemporal Degeneration (FTD) Center, the Amyotrophic Lateral Sclerosis (ALS) Center, the PD and Movement Disorder Clinic, and the Penn Udall Center for Parkinson's Research at the University of Pennsylvania [19]. The clinical or discovery cohort (n = 540) of clinically diagnosed participants included 165 AD, 105 MCI, 70 FTD (including 60 behavioral variant FTD and 10 corticobasal syndrome), 79 LB disorders (LBD; including 16 DLB and 63 PD or PD with dementia [PDD]), 41 ALS, 11 progressive supranuclear palsy (PSP), and 69 HC (see Table 1 and Supplementary Table 1). The validation cohort contained 102 neuropathologically confirmed cases, including 40 AD, 23 frontotemporal lobar degeneration with and without AD (FTLD; 17 FTLD, and 6 FTLD-AD), 30 PD or Lewy body–related pathology with and without AD (LRP) (three PD, four PD-AD, 21 LRP-AD, and two LRP with transactive response DNA-binding protein 43 pathology [LRP-TDP]), and six ALS (see below, Table 2, and Supplementary Table 2 for more details; note that three HC cases with an unremarkable burden of any significant brain pathology were not included

in the analyses in the present study due to the small case number). The clinical diagnoses were made by applying clinical diagnostic criteria for AD [1], behavioral variant FTD [20], corticobasal syndrome [21], primary progressive aphasia [22], DLB [23], PD or PDD [24,25], ALS [26], PSP [27], and HC as previously reported [19,28,29]. For the purposes of this study, patients diagnosed as corticobasal syndrome, behavioral variant FTD, FTD-motor neuron disease, progressive nonfluent aphasia, and semantic dementia were classified as FTD, whereas subjects with AD and logopenic progressive aphasia were classified as AD. As per current conventions, the term FTD was used for the clinical diagnosis, and the term FTLD for the neuropathologically confirmed diagnoses. Informed consent to be included in research studies and to perform the autopsy was obtained in all cases from the patients or legal representatives in accordance with the Pennsylvania state law. The study and all protocols were approved by the Institutional Review Boards of the University of Pennsylvania and the University of Washington.

2.2. CSF collection and CSF measurements

All CSF samples were obtained by lumbar puncture as described previously, and samples were immediately stored at -80°C until analysis [30]. CSF total α-syn and pS129 levels were measured at the University of Washington by using Luminex immunoassays as previously described [14,16]. CSF data for $A\beta_{42}$, t-tau, and p-tau were obtained at the University of Pennsylvania by using the INNO-BIA AlzBio3™ Luminex assay reagents (Innogenetics, Ghent, Belgium) [30–32]. CSF hemoglobin levels were measured as an index of red blood cell contamination, using a human hemoglobin ELISA quantitation kit (Bethyl Laboratories Inc, Montgomery, TX, USA) as previously described [14].

2.3. Tissue collection and neuropathological assessment

Tissue collection procedures have been previously described [19]. Briefly, a neuropathological diagnosis of AD was assigned if the probability was intermediate or high [33]. The diagnoses of FTLD-TAU, FTLD-TDP, and DLB were based on established criteria [23,34]. FTLD-TAU cases included cases with a diagnosis of argyrophilic grain disease, PSP, tangle predominant senile dementia, and corticobasal degeneration. See Supplementary Methods for more details.

2.4. Statistical analysis

All analyses were performed in SPSS 18.0 (IBM, Chicago, IL, USA) or Prism 6.0 (GraphPad Software, La Jolla, CA, USA). Immunoassay data (CSF total α-syn, pS129, $A\beta_{42}$, t-tau, and p-tau) were Log10 transformed to generate a more normally distributed data set, and the transformed data were used in all analyses. Correlations between biomarkers are reported as Pearson correlation coefficients. One way analysis of variance followed by Tukey post hoc

Table 1
Characteristics of the clinical cohort (CSF hemoglobin <500 ng/mL)

Characteristic	HC	AD	MCI	FTD		LBD		ALS	PSP
				bv-FTD	CBS	DLB	PD		
N	48	114	63	48	8	10	32	35	9
Age at CSF sampling*	67.3 (40–88)	69.5 (51–91)	70.5 (50–86)	62.6 (45–80)		66.0 (49–87)		55.3 (28–74)	70.4 (56–83)
Sex (F/M)	30/18	66/48	32/31	22/34		10/32		8/27	5/4
Disease duration at CSF (yr)*	-	2.9 (−1 to 16)	2.4 (−1 to 6)	2.8 (0 to 14)		6.6 (−1 to 22)		1.1 (0 to 10)	3.2 (0 to 7)
APOE ε4 presence (%)	29.2	50.0	38.1	28.6		23.8		20.0	11.1
CSF Aβ$_{42}$ (pg/mL)*	254.7 (94–423)	144.5 (31–405)	186.5 (78–355)	221.5 (82–386)		227.0 (78–338)		268.8 (8–464)	196.4 (110–347)
CSF t-tau (pg/mL)*	54.0 (20–161)	118.0 (21–405)	86.9 (18–254)	70.6 (7–203)		54.4 (20–127)		60.9 (21–271)	46.9 (18–80)
CSF p-tau (pg/mL)*	21.8 (2–101)	40.8 (7–135)	32.5 (5–116)	21.5 (4–62)		26.0 (10–69)		17.6 (6–196)	15.1 (7–23)
CSF t-tau/Aβ$_{42}$*	0.25 (0.09–1.02)	1.01 (0.08–4.87)	0.59 (0.08–2.13)	0.38 (0.09–1.63)		0.26 (0.09–0.92)		0.33 (0.08–3.63)	0.25 (0.14–0.53)
CSF p-tau/t-tau*	0.41 (0.05–1.00)	0.38 (0.12–1.23)	0.40 (0.12–1.07)	0.35 (0.07–1.14)		0.54 (0.16–1.00)		0.41 (0.07–6.76)	0.37 (0.16–0.65)
CSF α-syn (ng/mL)*	0.464 (0.179–0.753)	0.487 (0.219–0.913)	0.519 (0.180–0.889)	0.401 (0.082–0.884)		0.421 (0.142–0.859)		0.400 (0.119–0.847)	0.358 (0.138–0.625)
CSF pS129 (ng/mL)*	0.085 (0.044–0.159)	0.084 (0.044–0.159)	0.082 (0.051–0.157)	0.087 (0.053–0.199)		0.084 (0.044–0.134)		0.088 (0.049–0.156)	0.091 (0.062–0.157)
CSF pS129/α-syn*	0.205 (0.088–0.888)	0.191 (0.062–0.529)	0.176 (0.057–0.548)	0.268 (0.057–1.139)		0.238 (0.086–0.653)		0.270 (0.073–1.147)	0.300 (0.129–0.465)

Abbreviations: α-syn, α-synuclein; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; APOE, apolipoprotein E; bv-FTD, behavioral variant frontotemporal degeneration; CBS, corticobasal syndrome; CSF, cerebrospinal fluid; DLB, dementia with Lewy bodies; FTD, frontotemporal degeneration; HC, healthy controls; LBD, Lewy body disorders; MCI, mild cognitive impairment; PD, Parkinson disease; pS129, phosphorylated α-syn at Ser129; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau at Thr181; t-tau, total tau.

*Data shown are mean (range).

test was used to compare group means. Receiver operating characteristic (ROC) curves for analytes, controlling for age and sex of participants, were generated to evaluate their sensitivities and specificities in distinguishing AD from HC or diseased comparison participants. Area under curve (AUC) was determined as a measure of the overall performance of a diagnostic test (the closer the AUC is to 1, the better the overall diagnostic performance), which is also independent of disease prevalence because it is based on sensitivity and specificity [35]. The "optimum" cutoff value for an ROC curve was defined as the value associated with the maximal sum of sensitivity and specificity (i.e., maximizing the Youden index). Stepwise logistic regression was used to determine the best prediction models that included multiple CSF biomarkers as well as age and sex of participants. Values with $P < .05$ were regarded as significant.

3. Results

3.1. Correlation among CSF analytes in the whole cohort

A total of 642 cases were included in the present study. As previously described [14,15], CSF α-syn showed a strong association with CSF hemoglobin levels (an index of blood contamination in CSF; $r = 0.523$, $P < 3.8 \times 10^{-46}$) (Fig. 1A). CSF pS129 showed a significant, although weaker, inverse association with CSF hemoglobin levels ($r = -0.182$, $P < 3.6 \times 10^{-6}$) (Fig. 1B). When using a cutoff of hemoglobin >500 ng/mL in this cohort to exclude blood-contaminated samples, 31.3% of the CSF samples were excluded from all further analyses (n = 201) and then both CSF α-syn ($P = .869$) and pS129 ($P = .291$) showed no significant associations with CSF hemoglobin.

After excluding CSF samples with high hemoglobin levels (>500 ng/mL), CSF α-syn showed no association with CSF Aβ$_{42}$ ($r = -0.025$, $P = .597$) (Fig. 1C) but a strong positive correlation with t-tau ($r = 0.725$, $P < 1.5 \times 10^{-71}$) (Fig. 1D) as well as a moderate positive correlation with p-tau ($r = 0.430$, $P < 3.0 \times 10^{-21}$) (Fig. 1E). In contrast, CSF pS129 showed no association with any of the three classic AD CSF biomarkers (all $P > .07$). CSF α-syn and pS129 were not significantly correlated with each other ($r = -0.069$, $P = .15$) in this cohort (Fig. 1F).

3.2. Evaluation of diagnostic and differential diagnostic values of CSF α-syn and pS129 in the clinical cohort

A cohort of 540 cases without neuropathological confirmation was used as the discovery cohort in this study (see Supplementary Table 1 for the whole cohort). As described in the Section 2, certain disease groups were combined together based on their similar underlying pathology (e.g., DLB and PD/PDD) to increase the sample size in analyses. In this cohort (n = 367 subjects after excluding samples with high hemoglobin levels), CSF α-syn levels were numerically higher in AD than those in HC; LBD (DLB/PD/PDD; $P = .153$), or PSP ($P = .068$) (see Table 1 and

Table 2
Characteristics of the autopsy cohort (CSF hemoglobin <500 ng/mL)

Characteristic	AD	FTLD		LRP				ALS
		FTLD	FTLD-AD	PD	PD-AD	LRP-AD	LRP-TDP	
N	29	12	4	3	4	12	2	5
Age at CSF sampling*	70.7 (44–87)	66.4 (43–83)		70.0 (52–88)				57.4 (47–64)
Sex (F/M)	12/17	7/9		7/14				4/1
Disease duration at CSF (yr)*	3.1 (0–12)	3.1 (0–9)		5.3 (1–20)				1.2 (1–2)
Age at death*	76.1 (47–92)	70.7 (44–86)		74.9 (62–90)				59.4 (51–67)
Survival after CSF (yr)*	5.6 (1.5–13.9)	4.4 (1.2–10.4)		4.7 (1.1–10.7)				1.8 (0.2–4.0)
APOE ε4 presence (%)	55.2	12.5		52.4				20.0
CSF Aβ$_{42}$ (pg/mL)*	134.3 (39–295)	195.4 (108–275)		170.9 (85–274)				279.2 (203–343)
CSF t-tau (pg/mL)*	124.7 (20–304)	61.3 (22–143)		82.0 (22–196)				56.0 (25–102)
CSF p-tau (pg/mL)*	34.4 (5–94)	12.0 (4–45)		24.1 (4–83)				8.4 (6–12)
CSF t-tau/Aβ$_{42}$*	1.08 (0.21–3.40)	0.35 (0.15–1.15)		0.57 (0.13–1.72)				0.19 (0.12–0.30)
CSF p-tau/t-tau*	0.45 (0.04–4.70)	0.21 (0.04–0.55)		0.32 (0.07–0.83)				0.19 (0.10–0.40)
CSF α-syn (ng/mL)*	0.568 (0.248–1.120)	0.391 (0.216–0.698)		0.443 (0.227–0.725)				0.324 (0.197–0.579)
CSF pS129 (ng/mL)*	0.077 (0.044–0.107)	0.069 (0.051–0.103)		0.081 (0.046–0.138)				0.089 (0.071–0.106)
CSF pS129/α-syn*	0.156 (0.051–0.348)	0.192 (0.103–0.373)		0.196 (0.075–0.392)				0.323 (0.138–0.499)

Abbreviations: α-syn, α-synuclein; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; APOE, apolipoprotein E; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; FTLD-AD, frontotemporal lobar degeneration with Alzheimer's disease; LRP, Lewy body related pathology; LRP-AD, Lewy body related pathology with Alzheimer's disease; PD, Parkinson disease; pS129, phosphorylated α-syn at Ser129; p-tau, phosphorylated tau at Thr181; t-tau, total tau.
*Data shown are mean (range).

Fig. 2A). However, CSF α-syn was significantly higher in AD than in FTD (P = .004) or ALS (P = .014). CSF α-syn was also significantly higher in MCI than that in FTD (P = .001), LBD (P = .034), ALS (P = .003), or PSP (P = .023). CSF pS129 showed no differences between AD or MCI and HC, consistent with previous reports [16,36], or any other diagnostic groups (Fig. 2B). Using the CSF pS129/α-syn ratio did not enhance the performance of CSF total α-syn for AD diagnosis and differential diagnosis (Fig. 2C).

To further evaluate the diagnostic and differential diagnostic values of CSF biomarkers and their combinations, ROC analysis was performed to determine the sensitivities and specificities between AD and HC or patients with other neurodegenerative diseases (see Table 3 and Fig. 3). For the comparison between AD and HC, although CSF α-syn alone only provided a poor differentiation and as expected, CSF Aβ$_{42}$ (AUC = 0.890, 95% confidence interval [CI] 0.832–0.948; sensitivity = 86.8% [95% CI 79.2%–92.4%], specificity = 83.3% [95% CI 69.8%–92.5%]) or t-tau (AUC = 0.848, 95% CI 0.783–0.912; sensitivity = 77.2% [68.4%–84.5%], specificity = 83.3% [69.8%–92.5%]) could discriminate the two groups well, the best model was the combination of CSF Aβ$_{42}$, t-tau, and α-syn, when controlling for age and sex of participants (AUC = 0.931, 95% CI 0.890–0.973; sensitivity = 92.1% [85.5%–96.3%], specificity = 85.4% [72.2%–93.9%]; Fig. 3A).

For the comparison between AD and FTD groups, CSF α-syn alone (controlling for age and sex of participants) could provide a weak differentiation (AUC = 0.760, 95% CI 0.687–0.832; sensitivity = 51.8% [42.2%–61.2%], specificity = 89.3% [78.1%–96.0%]), similar to those of CSF Aβ$_{42}$, t-tau, or p-tau alone (Table 3); a combination of CSF α-syn, Aβ$_{42}$, and p-tau differentiated AD from FTD well (AUC = 0.893, 95% CI 0.845–0.941; sensitivity = 80.7% [72.3%–87.5%], specificity = 85.7% [73.8%–93.6%]; Fig. 3B) and was significantly more informative compared with the best individual CSF biomarker (Aβ$_{42}$; Z = 2.3744, P = .0176, DeLong's test [37]). Similarly, CSF α-syn alone could also provide a moderate differentiation for AD versus LBD (DLB/PD/PDD) (AUC = 0.751, 95% CI 0.664–0.838; sensitivity = 78.1% [69.4%–85.3%], specificity = 64.3% [48.0%–78.4%]), AD versus ALS (AUC = 0.858, 95% CI 0.788–0.928; sensitivity = 87.7% [80.3%–93.1%], specificity = 68.6% [50.7%–83.1%]), and AD versus PSP (AUC = 0.740, 95% CI 0.539–0.940; sensitivity = 70.2% [60.9%–78.4%], specificity = 77.8% [40.0%–97.2%]), and adding CSF α-syn to Aβ$_{42}$, t-tau (or p-tau) enhanced the differential diagnosis (AD versus LBD, AUC = 0.900, 95% CI 0.844–0.956, sensitivity = 89.5% [82.3%–94.4%], specificity = 82.1% [62.5%–92.5%], Fig. 3C; AD versus ALS, AUC = 0.947, 95% CI 0.883–1.000, sensitivity = 96.5% [91.3%–99.0%], specificity = 88.6% [73.3%–96.8%], Fig. 3D; and AD versus PSP, AUC = 0.915, 95% CI 0.860–0.970, sensitivity = 80.7% [72.3%–87.5%], specificity = 100.0% [66.4%–100%], Table 3).

3.3. Validation of differential diagnostic values of CSF biomarkers in the autopsy cohort

To further validate the differential diagnostic values, we measured the CSF biomarkers in a cohort of neuropathologically confirmed cases (n = 102 in total; 74 after excluding CSF samples with >500 ng/mL hemoglobin levels; see Table 2 and Supplementary Table 2). Due to the limited

number of cases, the subjects were categorized into the following pathological groups: AD, FTLD (including FTLD and FTLD-AD), LRP (including PD, PD-AD, LRP-AD, and LRP-TDP), and ALS. As shown in Fig. 4, consistent with the results from the clinical cohort, CSF α-syn was substantially higher in AD than that in FTLD, LRP, and ALS, whereas CSF pS129 did not show significant differences among diagnostic groups.

Further ROC analysis demonstrated that CSF α-syn could differentiate AD from FTLD (AUC = 0.782, P = .002, sensitivity = 58.6% [95% CI 38.9%–76.5%], specificity = 93.8% [69.8%–99.8%]; Fig. 4C), LRP (AUC = 0.678, P = .033, sensitivity = 79.3% [95% CI 60.3%–92.0%], specificity = 57.1% [34.0%–78.2%]; Fig. 4D), and ALS

(AUC = 0.966, P = .001, sensitivity = 86.2% [95% CI 68.3%–96.1%], specificity = 100.0% [47.8%–100.0%]) well, when controlling for age and sex of participants. In addition, the combinations of CSF α-syn, $A\beta_{42}$, and t-tau (or p-tau) further improved the differential diagnosis: AD versus FTLD, AUC = 0.935, P = 1.67×10^{-6}, sensitivity = 93.1% (95% CI 77.2%–99.2%), specificity = 87.5% (61.6%–98.4%) for a model of CSF α-syn, $A\beta_{42}$, and p-tau (Fig. 4E); AD versus LRP, AUC = 0.767, P = .001, sensitivity = 55.2% (95% CI 35.7%–73.6%), specificity = 95.2% (76.2%–99.9%) for a model of CSF α-syn, $A\beta_{42}$, and t-tau (Fig. 4F); and AD versus ALS, AUC = 1.000, P = 4.23×10^{-4}, sensitivity = 100.0% (95% CI 88.1%–100.0%),


Fig. 1. Association of CSF analytes. (A and B) Associations of CSF α-syn (A) and pS129 (B) with CSF hemoglobin values in all subjects (n = 642); vertical dashed red line represents the 500 ng/mL cutoff selected to exclude CSF α-syn values due to blood contamination. (C, D, and E) Associations of CSF α-syn with CSF $A\beta_{42}$ (C), t-tau (D), and p-tau at Thr181 p-tau (E), after excluding subjects with >500 ng/mL of CSF hemoglobin (n = 441 after exclusion). (F) Association of CSF α-syn and pS129 in subjects with ≤500 ng/mL hemoglobin. Abbreviations: α-syn, α-synuclein; $A\beta_{42}$, amyloid β peptide 1–42; CSF, cerebrospinal fluid; p-tau, phosphorylated tau; pS129, phosphorylated α-syn at Ser129; t-tau, total tau.

specificity = 100.0% (47.8%–100.0%) for a model of CSF α-syn, Aβ$_{42}$, and p-tau. It should be noted that some small sample sizes (e.g., n = 5 for ALS) led to wide 95% CIs.

4. Discussion

For the clinically relevant diagnosis and differential diagnosis of AD, it is essential to have a set of biomarkers that discriminate AD from other clinically relevant dementias or neurodegenerative diseases. Previous studies revealed substantial overlaps in CSF biomarker profiles (Aβ$_{42}$ and t-tau or p-tau) between AD and related disorders, and this significantly limits the utility of these core CSF biomarkers in differential diagnosis [5,6]. In the present study, we interrogated CSF samples obtained from a relatively large, longitudinally followed clinical cohort, and we report that higher CSF total α-syn might be relatively unique to AD and that by combining data on CSF measures of α-syn, Aβ$_{42}$, and t-tau or p-tau, we might be able to provide better diagnostic and differential diagnostic biomarker values for AD. These findings were largely confirmed in a separate cohort of participants who were longitudinally followed to autopsy for neuropathological confirmation of their diagnoses.

Although it was less apparent in the cohort included in this study, there is overlap of CSF Aβ$_{42}$ and tau values between AD and related disorders as reported in previous studies [5–9]. As discussed previously [5,6], these observations were not that surprising because mixed pathology is a common finding at autopsy [38–41], which may reflect converging pathophysiological mechanisms and pathways at late clinical stages [5]. For example, neuropathological and neuroimaging studies have revealed Aβ and tau pathology in LBD patients [42–44], and the regional brain Aβ accumulation appears to correlate with domain-specific cognitive performance in PD patients [45]. These results suggest that CSF Aβ$_{42}$ and tau may detect the increased levels of Aβ and tau pathology in non-AD diseases, limiting the differential diagnostic value of such biomarkers [5], particularly when used alone. Earlier studies [46,47] reported that CSF p-tau might improve the differential dementia diagnosis (AUC 0.6–0.8), but other large-scale studies [4,5], including the present study, found that CSF p-tau and t-tau performed largely equally.

In the present study, CSF α-syn levels tended to be higher in AD or MCI than those in related disorders in both cohorts, though the statistical significance was not achieved for AD versus HC and AD versus LBD (DLB/PD/PDD). This is in agreement with several previous large-scale studies, showing significantly higher levels of α-syn in CSF from patients with AD compared with HC [17,18,36] or patients with DLB/PDD [48]. The increase is perhaps due to the release of α-syn from damaged neurons during neurodegeneration, similar to what has been hypothesized for the increased levels of CSF tau in AD.


Fig. 2. CSF α-syn, pS129, and the pS129/α-syn ratio stratified by clinical diagnosis in the clinical cohort. (A and B) CSF total α-syn (A) and pS129 (B) concentrations were measured in the clinical cohort that includes patients with the diagnoses indicated below panel C. (C) The ratio of pS129/α-syn is also shown. The boxes extend from the 25th to 75th percentiles. The middle dark lines indicate the medians. The whiskers extend to 1.5 times the height of the box or, if no case has a value in that range, to the minimum or maximum values. Values not included between the whiskers are plotted as outliers with corresponding symbols. No outliers were excluded from the analyses in this study. Abbreviations: α-syn, α-synuclein; CSF, cerebrospinal fluid; pS129, phosphorylated α-syn at Ser129.

Table 3
Diagnostic and differential diagnostic values of CSF biomarkers in AD in the clinical cohort

Differential diagnosis	α-syn*	pS129/α-syn*	Aβ$_{42}$*	t-tau*	p-tau*	t-tau/Aβ$_{42}$*	Combined model[†]
AD versus HC							
AUC	0.573	0.573	0.890	0.848	0.789	0.891	0.931[‡]
Sensitivity%	58.8	71.9	86.8	77.2	78.9	90.4	92.1
Specificity%	60.4	45.8	83.3	83.3	72.9	81.3	85.4
P value	.142	.141	5.13E-15	3.03E-12	6.25E-9	4.56E-15	5.03E-18
AD versus FTD							
AUC	0.760	0.767	0.860	0.831	0.857	0.873	0.893[§]
Sensitivity%	51.8	58.8	79.8	73.7	68.4	76.3	80.7
Specificity%	89.3	82.1	80.4	78.6	89.3	87.5	85.7
P value	3.94E-8	1.55E-8	2.69E-14	2.35E-12	4.43E-14	4.94E-16	8.42E-17
AD versus LBD							
AUC	0.751	0.746	0.854	0.849	0.768	0.886	0.900[‡]
Sensitivity%	78.1	79.8	88.6	75.4	77.2	78.9	89.5
Specificity%	64.3	64.3	73.8	79.5	70.7	89.7	82.1
P value	1.57E-6	2.57E-6	1.27E-11	8.17E-11	3.59E-7	1.73E-13	9.50E-14
AD versus ALS							
AUC	0.858	0.859	0.939	0.912	0.942	0.939	0.947[§]
Sensitivity%	87.7	83.3	94.7	80.7	95.6	86.8	96.5
Specificity%	68.6	71.4	85.7	88.6	88.6	88.6	88.6
P value	1.61E-10	1.35E-10	4.65E-15	1.88E-13	2.72E-15	1.72E-15	1.32E-15
AD versus PSP							
AUC	0.740	0.788	0.715	0.882	0.889	0.900	0.915[‡]
Sensitivity%	70.2	78.1	76.3	67.5	81.6	90.4	80.7
Specificity%	77.8	77.8	66.7	100.0	88.9	88.9	100.0
P value	.017	.004	.032	1.41E-4	1.04E-4	4.34E-5	3.51E-5

Abbreviations: α-syn, α-synuclein; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; AUC, area under curve; CSF, cerebrospinal fluid; FTD, frontotemporal degeneration; HC, healthy controls; LBD, Lewy body disorders; pS129, phosphorylated α-syn at Ser129; PSP, progressive supranuclear palsy; p-tau, phosphorylated tau at Thr181; Sens, sensitivity; Spec, specificity; t-tau, total tau.

*Logistic model contains the CSF marker, age, and sex of participants.

[†]Logistic model contains CSF α-syn, Aβ$_{42}$, t-tau[‡] or p-tau[§], age, and sex of participants.

However, this cannot be the entire explanation because CSF α-syn and tau do not appear to be increased in most other neurodegenerative diseases that are also associated with α-syn or tau pathology and extensive neuron loss in the brain. We have reported that CSF α-syn and tau could be transported from the central nervous system into peripheral blood, and this potential clearance of central nervous system α-syn and tau via exosomes appeared to be increased in PD compared with HC [49,50] but not in AD for tau [50] (α-syn clearance in AD has not been tested yet). Whether this is also true for central nervous system α-syn clearance and whether it could be a major contributor to the increase of CSF α-syn and tau in AD needs further investigation.

Most importantly, we found that the diagnostic accuracy of the combinations of these CSF biomarkers including measures of α-syn, Aβ, and tau was high enough (AUC, 0.8–0.9) to be useful in clinical settings for differentiating patients with AD from those with other related disorders. The diagnostic accuracy of these CSF proteins for differentiating AD from FTD is at least in the same order of magnitude as those obtained with advanced neuroimaging technologies [51,52] and at a lower cost. Our findings on AD versus LBD are also in line with a previous study [48] reporting that a panel of CSF biomarkers including α-syn, tau, and Aβ$_{42}$ could differentiate AD from DLB and PDD with high

sensitivity and specificity. It should be emphasized that these results were acquired from a retrospective study under a research setting and the biomarker accuracy and usefulness of the panel need to be further confirmed in prospective diagnostic studies under clinical settings [4]. In addition, we used AUC as well as the Youden index–determined sensitivity and specificity in this study to assess the overall performance of candidate biomarkers for the differential diagnosis of AD, which usually has higher prevalence rate among related diseases. In some clinical settings (e.g., to screen for a certain disease of very low prevalence, a high specificity, and a low false positive rate is required), the performance may need to be re-evaluated by adjusting the cutoff range or considering only a portion of the ROC curve.

However, CSF pS129 levels did not distinguish AD from any of the other diagnostic groups in this study. Previous studies have demonstrated that pS129 is the predominant post-translationally modified form of α-syn in LBs [53,54] and have also associated CSF pS129 with PD [16,55]. However, the role of pS129 in AD remains unclear despite the frequent observation of LBs in AD brains [11–13]. In our previous study [16], we did not observe significant differences in CSF pS129 levels between AD and HC when a small cohort of AD subjects was examined. This was confirmed in a more recent independent study with a much larger AD cohort [36]. In the present study, CSF pS129 and total α-syn were

Fig. 3. ROC analysis of CSF biomarkers in the clinical cohort. (A) AD versus HC; (B) AD versus FTD/CBS; (C) AD versus DLB/PD; (D) AD versus ALS. Blue dashed line indicates CSF α-syn alone, orange dot-dashed line indicates CSF Aβ$_{42}$, black dotted line indicates CSF t-tau or p-tau, and red solid line indicates a combined model of CSF α-syn, Aβ$_{42}$, and t-tau or p-tau. Abbreviations: AD, Alzheimer's disease; Aβ$_{42}$, amyloid β peptide 1–42; CSF, cerebrospinal fluid; p-tau, phosphorylated tau; t-tau, total tau; HC, healthy controls; α-syn, α-synuclein; DLB, dementia with Lewy bodies; PD, Parkinson disease; FTD, frontotemporal degeneration; ALS, amyotrophic lateral sclerosis; CBS, corticobasal syndrome; ROC, Receiver operating characteristic.

not significantly correlated with each other, indicating that different α-syn forms in CSF might behave differently, possibly due to different transportation or clearance mechanisms. Our results also suggest that the transportation or clearance mechanisms for pS129, if different from general α-syn species, might be less likely affected under different disease settings.

All the ROC analyses in this study were performed by controlling for age and sex of participants. Several studies have explored whether demographic factors, including age, sex, and the apolipoprotein E (*APOE*) ε4 genotype, impact the diagnostic accuracy of CSF AD biomarkers (see review by Mattsson et al. [4]). Although there is no clear effect of sex on the diagnostic accuracy, age may impact the diagnostic performance of CSF AD biomarkers [4]. The genotype *APOE* ε4 is strongly associated with reduced CSF Aβ$_{42}$ in

controls but not with altered CSF t-tau or p-tau levels [4] as well as CSF α-syn levels [17]. However, because *APOE* ε4 is associated with increased amyloid pathology, rather than artificial reductions of CSF Aβ$_{42}$, it is not recommended to adjust the CSF Aβ$_{42}$ cutoff depending on the presence of *APOE* ε4 [4]. In the present study, adding *APOE* ε4 status to the models did not change the outcomes (data not shown).

One limitation of this study is that the cohort studied here did not include any subjects with vascular dementia and thus the performance of CSF α-syn, together with Aβ$_{42}$ and t-tau or p-tau, on differentiating AD from vascular dementia remains unknown. Although this needs to be further investigated in future studies, we previously reported that CSF E-selectin, a biomarker of endothelial function or vascular injury, might be a promising CSF biomarker to pursue as a potential indicator that vascular

Fig. 4. CSF α-syn and pS129 stratified by autopsy diagnosis and the differential diagnosis performance of CSF biomarkers in the validation (autopsy) cohort. (A and B) CSF α-syn (A) and pS129 (B) concentrations were measured in the cohort. (C and D) CSF α-syn contributed to the differential diagnosis of AD: AD versus FTLD (C), and AD versus LRP (D). Abbreviations: α-syn, α-synuclein; Aβ$_{42}$, amyloid β peptide 1–42; AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; CSF, cerebrospinal fluid; FTLD, frontotemporal lobar degeneration; LRP, Lewy body related pathology; pS129, phosphorylated α-syn at Ser129; p-tau, phosphorylated tau; t-tau, total tau.

pathology is contributing to dementia [56]. Thus, CSF E-selectin should be tested in larger cohorts for its ability to differentiate AD from vascular dementia. Another potential limitation is that certain disease groups with similar underlying pathology were combined together (e.g., DLB and PD were combined into overarching LBD or LRP) to increase the sample size in the analyses, and its potential confounding effects need to be further investigated in future larger-scale studies.

In summary, CSF total α-syn, when combined with core AD biomarkers (i.e., Aβ$_{42}$, t-tau, and p-tau), improved the differential diagnosis of AD versus FTD, LBD (DLB/PD/PDD) and other neurodegenerative diseases. The diagnostic accuracy of the combined models described here was high enough to be of clinical value for differentiating AD patients from patients with other related disorders in our cohort. Moreover, the diagnostic performance of these CSF biomarkers was supported by studies of a second cohort of subjects who were longitudinally followed to autopsy for neuropathological confirmation of their diagnoses. Although further validation in independent cohorts is still needed, our results indicate that CSF measures of total α-syn combined with measures of Aβ$_{42}$, t-tau, and p-tau might have clinical value in the differential diagnosis of AD.

Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jalz.2018.02.015.

RESEARCH IN CONTEXT

1. Systematic review: The Pubmed database was searched to identify previously published research. Differential diagnosis of Alzheimer's disease (AD) from other common geriatric dementing disorders remains unresolved. Recent studies found that the utility of the core cerebrospinal fluid (CSF) AD biomarkers (amyloid β peptide 1–42, total tau, and phosphorylated tau) to discriminate AD from a variety of related disorders is limited, probably due to overlap in the underlying primary pathologies. It has been suggested that introduction of additional CSF biomarkers reflecting other types of pathologies could optimize differential diagnosis.

2. Interpretation: Our findings indicate that CSF measures of total α-synuclein combined with measures of amyloid β peptide 1–42, total tau, and phosphorylated tau, representing Lewy body and AD pathologies, respectively, likely have clinical value in the differential diagnosis of AD.

3. Future directions: Further studies are needed to include additional CSF biomarkers to reflect other comorbid pathologies, such as E-selectin for vascular pathology commonly observed at autopsy of AD brains.

References

[1] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263–9.

[2] Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6:131–44.

[3] Blennow K, Zetterberg H. The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci 2015;9:345.

[4] Mattsson N, Lonneborg A, Boccardi M, Blennow K, Hansson O. Clinical validity of cerebrospinal fluid Abeta42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiol Aging 2017;52:196–213.

[5] Ewers M, Mattsson N, Minthon L, Molinuevo JL, Antonell A, Popp J, et al. CSF biomarkers for the differential diagnosis of Alzheimer's disease: A large-scale international multicenter study. Alzheimers Dement 2015;11:1306–15.

[6] Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012;78:47–54.

[7] Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, et al. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 2004;61:95–102.

[8] Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Trenkwalder C, et al. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry 2007;12:671–80.

[9] Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic accuracy of cerebrospinal fluid amyloid-beta isoforms for early and differential dementia diagnosis. J Alzheimers Dis 2015;45:813–22.

[10] Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 2012;124:23–35.

[11] Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, et al. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998;153:1365–70.

[12] Lippa CF, Schmidt ML, Lee VM, Trojanowski JQ. Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Ann Neurol 1999;45:353–7.

[13] Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol 2000;10:378–84.

[14] Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010;133:713–26.

[15] Shi M, Bradner J, Hancock AM, Chung KA, Quinn JF, Peskind ER, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570–80.

[16] Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, et al. Phosphorylated α-synuclein in Parkinsonian disorders. Sci Transl Med 2012;4:121ra20.

[17] Korff A, Liu C, Ginghina C, Shi M, Zhang J. Alpha-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment. J Alzheimers Dis 2013;36:679–88.

[18] Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF alpha-synuclein improves diagnostic and prognostic performance of CSF tau and Abeta in Alzheimer's disease. Acta Neuropathol 2013; 126:683–97.

[19] Toledo JB, Van Deerlin VM, Lee EB, Suh E, Baek Y, Robinson JL, et al. A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. Alzheimers Dement 2014;10:477–484.e1.

[20] Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134:2456–77.

[21] Grossman M, Libon DJ, Forman MS, Massimo L, Wood E, Moore P, et al. Distinct antemortem profiles in patients with pathologically defined frontotemporal dementia. Arch Neurol 2007;64:1601–9.

[22] Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. Neurology 2011;76:1006–14.

[23] McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.

[24] Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.

[25] Dubois B, Burn D, Goetz C, Aarsland D, Brown RG, Broe GA, et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 2007;22:2314–24.

[26] Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293–9.

[27] Litvan I, Hauw JJ, Bartko JJ, Lantos PL, Daniel SE, Horoupian DS, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol 1996;55:97–105.

[28] Xie SX, Libon DJ, Wang X, Massimo L, Moore P, Vesely L, et al. Longitudinal patterns of semantic and episodic memory in frontotemporal lobar degeneration and Alzheimer's disease. J Int Neuropsychol Soc 2010;16:278–86.

[29] Xie SX, Ewbank DC, Chittams J, Karlawish JH, Arnold SE, Clark CM. Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale. Alzheimer Dis Assoc Disord 2009;23:268–74.

[30] Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 2005;57:721–9.

[31] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403–13.

[32] Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, et al. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005;51:336–45.

[33] Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095–7.

[34] Mackenzie I, Neumann M, Bigio E, Cairns N, Alafuzoff I, Kril J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol 2010;119:1–4.

[35] Obuchowski NA. Receiver operating characteristic curves and their use in radiology. Radiology 2003;229:3–8.

[36] Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer's disease. Sci Rep 2017;7:40263.

[37] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.

[38] Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001;357:169–75.

[39] Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007;69:2197–204.

[40] Sonnen JA, Postupna N, Larson EB, Crane PK, Rose SE, Montine KS, et al. Pathologic correlates of dementia in individuals with Lewy body disease. Brain Pathol 2010;20:654–9.

[41] Wang BW, Lu E, Mackenzie IR, Assaly M, Jacova C, Lee PE, et al. Multiple pathologies are common in Alzheimer patients in clinical trials. Can J Neurol Sci 2012;39:592–9.

[42] Gomez-Isla T, Growdon WB, McNamara M, Newell K, Gomez-Tortosa E, Hedley-Whyte ET, et al. Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999; 53:2003–9.

[43] Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903–10.

[44] Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. Lancet Neurol 2017;16:55–65.

[45] Akhtar RS, Xie SX, Chen YJ, Rick J, Gross RG, Nasrallah IM, et al. Regional brain amyloid-beta accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia. PLoS ONE 2017;12:e0177924.

[46] Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, et al. Cerebrospinal Fluid P-Tau181P: Biomarker for Improved Differential Dementia Diagnosis. Front Neurol 2015; 6:138.

[47] Tang W, Huang Q, Yao YY, Wang Y, Wu YL, Wang ZY. Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm (Vienna) 2014;121:1541–53.

[48] Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol 2012;69:1445–52.

[49] Shi M, Liu C, Cook TJ, Bullock KM, Zhao Y, Ginghina C, et al. Plasma exosomal alpha-synuclein is likely CNS-derived and increased in Parkinson's disease. Acta Neuropathol 2014;128:639–50.

[50] Shi M, Kovac A, Korff A, Cook TJ, Ginghina C, Bullock KM, et al. CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease. Alzheimers Dement 2016; 12:1125–31.

[51] Moller C, Pijnenburg YA, van der Flier WM, Versteeg A, Tijms B, de Munck JC, et al. Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. Radiology 2016;279:838–48.

[52] Bron EE, Smits M, Papma JM, Steketee RM, Meijboom R, de Groot M, et al. Multiparametric computer-aided differential diagnosis of Alzheimer's disease and frontotemporal dementia using structural and advanced MRI. Eur Radiol 2017;27:3372–82.

[53] Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006;281:29739–52.

[54] Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160–4.

[55] Majbour NK, Vaikath NN, van Dijk KD, Ardah MT, Varghese S, Vesterager LB, et al. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Mol Neurodegener 2016;11:7.

[56] Li G, Xiong K, Korff A, Pan C, Quinn JF, Galasko DR, et al. Increased CSF E-Selectin in Clinical Alzheimer's Disease without Altered CSF Abeta42 and Tau. J Alzheimers Dis 2015;47:883–7.